SCHEMBL6288260

SCHEMBL6288260

CC(Cc1ccc2c(c1)OCO2)NCCCCN1C(=O)C=CC1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.53
SLC6A4 P31645 3/20 0.53
SLC6A2 P23975 2/20 0.53
SLC6A3 Q01959 2/20 0.53
CYP2D6 P10635 2/20 0.53
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
TSHR P16473 1/20 0.44
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
ADRB3 P13945 1/20 0.43
ADRA1D P25100 1/20 0.43
ADRA1A P35348 1/20 0.43
ADRA1B P35368 1/20 0.43
CMA1 P23946 1/20 0.43
NPSR1 Q6W5P4 1/20 0.41
CYP3A4 P08684 1/20 0.40
GAA P10253 1/20 0.40
HSD17B10 Q99714 1/20 0.40
DPP7 Q9UHL4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5305354 0.81 TAAR1 (0.63) TAAR1SLC6A4SLC6A2SLC6A3CYP2D6
SCHEMBL5473006 0.80 TAAR1 (0.62) TAAR1SLC6A4SLC6A2SLC6A3CYP2D6
SCHEMBL6284795 0.80 TAAR1 (0.62) TAAR1SLC6A4SLC6A2SLC6A3CYP2D6
SCHEMBL5469153 0.80 TAAR1 (0.62) TAAR1SLC6A4SLC6A2SLC6A3CYP2D6
SCHEMBL5291239 0.80 TAAR1 (0.65) TAAR1SLC6A4SLC6A2SLC6A3CYP2D6
SCHEMBL30249027 0.80 TAAR1 (0.65) TAAR1SLC6A4SLC6A2SLC6A3CYP2D6
SCHEMBL2418816 0.77 TAAR1 (0.68) TAAR1SLC6A4SLC6A2SLC6A3CYP2D6
SCHEMBL29633088 0.77 TAAR1 (0.68) TAAR1SLC6A4SLC6A2SLC6A3CYP2D6
SCHEMBL25532944 0.77 TAAR1 (0.68) TAAR1SLC6A4SLC6A2SLC6A3CYP2D6
SCHEMBL5471876 0.76 SLC6A4 (0.67) TAAR1SLC6A4SLC6A2SLC6A3CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6946547-B2 Ecstasy-class analogs and use of same in detection of ecstasy-class compounds MICROGENICS CORPORATION (US) 2005-09-20 US disclosed
US-20030207469-A1 Ecstasy-class analogs and use of same in detection of ecstasy-class compounds MICROGENICS CORPORATION (US) 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207469-A1 Ecstasy-class analogs and use of same in detection of ecstasy-class compounds CES2, DNPEP, HLA-A TAAR1 359/4885SLC6A4 208/4885SLC6A2 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.